AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
130_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
ADDITIONAL_NN
INFORMATION_NOMZ
FOR_PIN
US_FPP1
INVESTORS_NN
INTRODUCTION_NOMZ
Capitalisation_NOMZ
of_PIN
interest_NN
New_NN
accounting_GER
standards_NN
adopted_VBN
The_DT
accompanying_VBG
consolidated_JJ
Financial_NN
AstraZeneca_NN
does_VPRT
not_XX0
capitalize_VB
interest_NN
under_IN
AstraZeneca_NN
has_VPRT [PEAS]
adopted_VBN
the_DT
provisions_NN
of_PIN
SFAS_NN
Statements_NOMZ
included_VBD
in_PIN
this_DEMO
Annual_JJ
Report_NN
IFRS_NN
._.
US_FPP1
GAAP_NN
requires_VPRT [SUAV] [THATD]
interest_NN
incurred_VBN
No._NN
._.
123_CD
R_NN
Share-Based_NN
Payment_NOMZ
in_PIN
2005_CD
._.
are_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
IFRS_NN
as_IN
as_IN
part_NN
of_PIN
the_DT
cost_NN
of_PIN
constructing_VBG
property_NN
,_,
SFAS_NN
No._NN
._.
123_CD
R_NN
requires_VPRT [SUAV]
compensation_NOMZ
cost_NN
adopted_VBN [WZPAST]
by_PIN
the_DT
EU_NN
._.
There_EX
are_VPRT
certain_JJ
significant_JJ
plant_NN
and_PHC
equipment_NOMZ
to_TO
be_VB [PASS]
capitalized_VBN
and_PHC
related_VBN
to_PIN
share-based_JJ
payments_NOMZ
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
differences_NN
between_PIN
IFRS_NN
and_PHC
US_FPP1
GAAP_NN
amortised_VBD
over_IN
the_DT
life_NN
of_PIN
the_DT
asset_NN
._.
AstraZeneca_NN
has_VPRT
which_WDT
affect_VPRT
AstraZenecas_NN
net_JJ
income_NN
and_CC
followed_VBD
the_DT
transitional_JJ
arrangements_NOMZ
for_PIN
shareholders_NN
equity_NOMZ
and_CC
,_,
on_PIN
pages_NN
130_CD
to_PIN
Deferred_JJ
taxation_NOMZ
modified_VBD
retrospective_JJ
application_NOMZ
in_PIN
adopting_VBG
136_CD
,_,
additional_JJ
information_NOMZ
under_IN
US_FPP1
GAAP_NN
Under_IN
IFRS_NN
,_,
full_JJ
provision_NN
for_PIN
deferred_VBN
taxation_NOMZ
SFAS_NN
No._NN
._.
123_CD
R._NN
As_CONJ
a_NULL
consequence_NULL
,_,
the_DT
is_VPRT [PASS]
set_VBN
out_PIN
as_IN
follows_VPRT
:_:
is_VPRT [PASS]
made_VBN
although_CONC
there_EX
are_VPRT
a_DT
number_NN
of_PIN
2004_CD
comparative_JJ
US_FPP1
GAAP_NN
income_NN
before_IN
different_JJ
bases_NN
from_PIN
US_FPP1
GAAP_NN
on_PIN
which_WDT [PIRE]
this_DEMO
tax_NN
has_VPRT [PEAS]
been_VBN [BYPA]
reduced_VBN
by_PIN
$_$
147m_CD
with_PIN
a_DT
related_JJ
Summary_NN
of_PIN
differences_NN
between_PIN
IFRS_NN
and_PHC
calculation_NOMZ
is_VPRT [PASS]
made_VBN
:_:
for_CONJ
example_NULL
,_,
the_DT
elimination_NOMZ
tax_NN
credit_NN
of_PIN
$_$
58m_CD
and_CC
the_DT
shareholders_NN
US_FPP1
GAAP_NN
accounting_GER
principles_NN
:_:
page_NN
130_CD
._.
of_PIN
intra-group_JJ
profit_NN
on_PIN
inventories_NN
and_PHC
shareequity_NOMZ
at_PIN
31_CD
December_NN
2004_CD
increased_VBN
by_PIN
Net_JJ
income_NN
:_:
page_NN
131_CD
._.
based_VBN
payment_NOMZ
transactions_NOMZ
._.
The_DT
impact_NN
in_PIN
2003_CD
was_VBD
to_TO
reduce_VB
US_FPP1
GAAP_NN
condensed_JJ
consolidated_JJ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
full_JJ
liability_NOMZ
basis_NN
under_IN
US_FPP1
GAAP_NN
,_,
income_NN
before_IN
tax_NN
by_PIN
$_$
154m_CD
with_PIN
a_DT
related_JJ
tax_NN
statement_NOMZ
of_PIN
operations_NOMZ
:_:
page_NN
131_CD
._.
which_WDT [SERE]
requires_VPRT [SUAV]
deferred_VBN
tax_NN
assets_NN
to_TO
be_VB
credit_NN
of_PIN
$_$
23m_CD
and_CC
increase_VB
shareholders_NN
US_FPP1
GAAP_NN
statement_NOMZ
of_PIN
comprehensive_JJ
recognized_VBN [PRIV]
without_PIN
a_DT
valuation_NOMZ
allowance_NN
equity_NOMZ
at_PIN
31_CD
December_NN
2003_CD
by_PIN
$_$
105m_CD
._.
income_NN
:_:
page_NN
132_CD
._.
if_COND
their_TPP3
realisation_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
more_EMPH
Stock-based_JJ
compensation_NOMZ
:_:
page_NN
132_CD
._.
likely_RB
than_PIN
not_XX0
._.
New_NN
accounting_GER
standards_NN
not_XX0
adopted_VBN
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
:_:
In_PIN
November_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
page_NN
132_CD
._.
Pension_NN
and_CC
post-retirement_JJ
benefits_NN
No._NN
._.
151_CD
Inventory_NN
Costs_NN
to_TO
clarify_VB
the_DT
Taxation_NOMZ
:_:
page_NN
134_CD
._.
IFRS_NN
requires_VPRT [SUAV]
that_THVC
in_PIN
respect_NN
of_PIN
defined_VBN
benefit_NN
accounting_GER
for_PIN
abnormal_JJ
amounts_NN
of_PIN
idle_JJ
Shareholders_NN
equity_NOMZ
:_:
page_NN
135_CD
._.
plans_NN
,_,
obligations_NOMZ
are_VPRT [PASS]
measured_VBN
at_PIN
discounted_JJ
facility_NOMZ
expense_NN
,_,
freight_NN
,_,
handling_VBG
costs_NN
and_CC
Acquired_VBN
intangible_JJ
assets_NN
and_PHC
goodwill_NN
:_:
fair_JJ
value_NN
whilst_OSUB
plan_NN
assets_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
fair_JJ
wasted_VBN
material_NN
spoilage_NN
._.
The_DT
operating_GER
and_PHC
financing_GER
costs_NN
of_PIN
is_VPRT [BEMA]
effective_PRED
for_PIN
inventory_NN
costs_NN
incurred_VBN [WZPAST]
during_PIN
US_FPP1
GAAP_NN
condensed_JJ
consolidated_JJ
such_JJ
plans_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
separately_RB
in_PIN
the_DT
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15_CD
June_NN
2005_CD
._.
statement_NOMZ
of_PIN
cash_NN
flows_NN
:_:
page_NN
136_CD
._.
income_NN
statement_NOMZ
:_:
service_NN
costs_NN
are_VPRT [PASS]
spread_VBN
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
151_CD
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
systematically_RB
over_IN
the_DT
lives_NN
of_PIN
employees_NN
and_CC
to_TO
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
results_NN
or_CC
net_JJ
DIFFERENCES_NN
BETWEEN_PIN
INTERNATIONAL_NN
financing_GER
costs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
periods_NN
assets_NN
of_PIN
AstraZeneca_NN
._.
AND_ANDC
US_FPP1
ACCOUNTING_GER
PRINCIPLES_NN
in_PIN
which_WDT [PIRE]
they_TPP3
arise_VPRT
._.
US_FPP1
GAAP_NN
adopts_VPRT
a_DT
similar_JJ
Purchase_NN
accounting_GER
adjustments_NOMZ
approach_VPRT
._.
Under_IN
IFRS_NN
,_,
actuarial_JJ
gains_NN
and_CC
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
Under_IN
IFRS_NN
,_,
the_DT
merger_NN
of_PIN
Astra_NN
and_PHC
Zeneca_NN
losses_NN
are_VPRT [PASS]
permitted_VBN
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
No._NN
._.
152_CD
Accounting_GER
for_PIN
Real_NN
Estate_NN
Timeis_NN
accounted_VBD
for_PIN
as_IN
a_DT
merger_NN
of_PIN
equals_VPRT
poolingimmediately_RB
in_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
sharing_GER
Transactions_NOMZ
,_,
an_DT
amendment_NOMZ
of_PIN
FASB_NN
of-interests_NN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
business_NOMZ
income_NN
and_PHC
expense_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
such_JJ
Statements_NOMZ
No._NN
._.
66_CD
and_CC
67_CD
which_WDT
provides_VPRT
that_DEMO
combinations_NOMZ
exemption_NOMZ
permitted_VBN [WZPAST]
by_PIN
IFRS_NN
1_CD
actuarial_JJ
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
permitted_VBN
to_PIN
real_JJ
estate_NN
time-sharing_JJ
transactions_NOMZ
should_NEMD
First-time_JJ
Adoption_NOMZ
of_PIN
International_NN
Financial_NN
be_VB [PASS]
amortised_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
be_VB [PASS]
accounted_VBN
for_PIN
as_IN
non-retail_JJ
land_NN
sales_NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
average_JJ
remaining_VBG
service_NN
period_NN
of_PIN
employees_NN
._.
152_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
merger_NN
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
the_DT
acquisition_NOMZ
A_DT
minimum_JJ
pension_NN
liability_NOMZ
is_VPRT [SPAU] [PASS]
also_RB
recognized_VBN [PRIV]
after_IN
15_CD
June_NN
2005_CD
._.
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
of_PIN
Astra_NN
by_PIN
Zeneca_NN
using_VBG [WZPRES]
purchase_NN
accounting_GER
._.
through_PIN
other_JJ
comprehensive_JJ
income_NN
in_PIN
No._NN
._.
152_CD
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
have_VB
a_DT
material_NN
effect_NN
Under_IN
purchase_NN
accounting_GER
,_,
the_DT
assets_NN
and_CC
certain_JJ
circumstances_NN
when_RB
there_EX
is_VPRT
a_DT
deficit_NN
on_PIN
the_DT
net_JJ
assets_NN
or_CC
results_NN
of_PIN
AstraZeneca_NN
._.
liabilities_NOMZ
of_PIN
the_DT
acquired_VBN
entity_NOMZ
are_VPRT [PASS]
recorded_VBN
of_PIN
plan_NN
assets_NN
relative_JJ
to_PIN
the_DT
accumulated_VBN
at_PIN
fair_JJ
value_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
fair_JJ
value_NN
benefits_NN
obligation_NOMZ
._.
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
exercise_NN
,_,
increases_NN
in_PIN
the_DT
values_NN
of_PIN
Astras_NN
No._NN
._.
153_CD
Exchanges_NN
of_PIN
Non-monetary_JJ
Assets_NN
,_,
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_PHC
inventory_NN
Intangible_JJ
assets_NN
an_DT
amendment_NOMZ
of_PIN
APB_NN
Opinion_NN
No._NN
._.
29_CD
which_WDT
were_VBD [PASS]
recognized_VBN [PRIV]
and_PHC
values_VPRT
attributed_VBN
to_PIN
its_PIT
Under_IN
IFRS_NN
,_,
certain_JJ
payments_NOMZ
for_PIN
rights_NN
replaces_VPRT
the_DT
current_JJ
exception_NOMZ
from_PIN
fair_JJ
value_NN
in-process_JJ
research_NN
and_PHC
development_NOMZ
and_CC
to_PIN
compounds_NN
in_PIN
development_NOMZ
are_VPRT [PASS]
capitalized_VBN
._.
measurement_NOMZ
for_PIN
non-monetary_JJ
exchanges_NN
existing_VBG [WZPRES]
products_NN
,_,
together_RB
with_PIN
appropriate_JJ
Under_IN
US_FPP1
GAAP_NN
,_,
these_DEMO
payments_NOMZ
are_VPRT [BEMA]
of_PIN
similar_JJ
productive_JJ
assets_NN
with_PIN
a_DT
general_JJ
deferred_JJ
taxation_NOMZ
effects_NN
._.
The_DT
difference_NN
between_PIN
generally_RB
expensed_VBN
._.
exception_NOMZ
from_PIN
fair_JJ
value_NN
measurement_NOMZ
for_PIN
the_DT
cost_NN
of_PIN
investment_NOMZ
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
exchanges_NN
of_PIN
non-monetary_JJ
assets_NN
that_TSUB
do_VPRT [PROD]
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
Astra_NN
was_VBD [PASS]
recorded_VBN
as_IN
Financial_NN
instruments_NOMZ
and_CC
hedging_VBG
activities_NOMZ
not_XX0
have_VPRT
commercial_JJ
substance_NN
._.
The_DT
amount_NN
allocated_VBN [WZPAST]
to_PIN
in-process_JJ
Under_IN
IFRS_NN
,_,
certain_JJ
financial_JJ
assets_NN
and_CC
certain_JJ
shall_PRMD
be_VB [PASS]
applied_VBN
prospectively_RB
and_CC
is_VPRT [BEMA]
effective_JJ
research_NN
and_PHC
development_NOMZ
was_VBD
,_,
as_IN
required_VBN [SUAV] [THATD]
financial_JJ
liabilities_NOMZ
including_VBG [WZPRES]
derivatives_NN
are_VPRT [BEMA]
for_PIN
non-monetary_JJ
asset_NN
exchanges_NN
occurring_VBG [WZPRES]
by_PIN
US_FPP1
GAAP_NN
,_,
expensed_VBD
immediately_TIME
in_PIN
the_DT
first_JJ
recognized_VBN [PRIV]
at_PIN
fair_JJ
value_NN
:_:
movements_NOMZ
in_PIN
the_DT
fair_JJ
in_PIN
fiscal_JJ
periods_NN
beginning_VBG [WZPRES]
after_IN
15_CD
June_NN
2005_CD
._.
reporting_VBG [PUBV]
period_NN
after_IN
the_DT
business_NOMZ
combination_NOMZ
._.
value_NN
may_POMD
be_VB [PASS]
recorded_VBN
in_PIN
equity_NOMZ
or_CC
through_PIN
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
153_CD
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
Fair_NN
value_NN
adjustments_NOMZ
to_PIN
the_DT
recorded_VBN
amount_NN
income_NN
,_,
depending_VBG [PRESP]
upon_PIN
their_TPP3
designation_NOMZ
._.
to_TO
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
results_NN
or_CC
net_NN
of_PIN
inventory_NN
were_VBD [PASS]
expensed_VBN
in_PIN
the_DT
period_NN
the_DT
Under_IN
US_FPP1
GAAP_NN
,_,
marketable_JJ
securities_NOMZ
are_VPRT
assets_NN
of_PIN
AstraZeneca_NN
._.
Additional_JJ
amortisation_NOMZ
recognized_VBN [PRIV] [WZPAST]
at_PIN
fair_JJ
value_NN
,_,
with_PIN
movements_NOMZ
in_PIN
fair_JJ
and_CC
depreciation_NOMZ
have_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
recorded_VBN
in_PIN
value_NN
taken_VBN [WZPAST]
to_PIN
a_DT
separate_JJ
component_NN
of_PIN
equity_NOMZ
._.
In_PIN
May_POMD
2005_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
154_CD
respect_NN
of_PIN
the_DT
fair_JJ
value_NN
adjustments_NOMZ
to_PIN
tangible_JJ
Derivatives_NN
are_VPRT [SPAU] [PASS]
also_RB
measured_VBN
at_PIN
fair_JJ
value_NN
with_PIN
Accounting_GER
Changes_NN
and_PHC
Error_NN
Corrections_NOMZ
and_CC
intangible_JJ
assets_NN
._.
However_CONJ
,_,
a_DT
replacement_NOMZ
of_PIN
APB_NN
Opinion_NN
No._NN
._.
20_CD
and_CC
FASB_NN
financial_JJ
liabilities_NOMZ
are_VPRT [PASS]
recorded_VBN
at_PIN
amortised_JJ
cost_NN
._.
154_CD
requires_VPRT [SUAV]
Under_IN
IFRS_NN
,_,
up_RB
until_IN
31_CD
December_NN
2002_CD
,_,
retrospective_JJ
application_NOMZ
of_PIN
prior_JJ
periods_NN
goodwill_NN
was_VBD [PASS]
required_VBN [SUAV]
to_TO
be_VB [PASS]
capitalized_VBN
and_CC
financial_JJ
statements_NOMZ
for_PIN
changes_NN
in_PIN
accounting_GER
amortised_VBN
._.
154_CD
applies_VPRT
to_PIN
accounting_GER
is_VPRT [PASS]
tested_VBN
annually_RB
for_PIN
impairment_NOMZ
but_CC
not_XX0
periods_NN
beginning_VBG [WZPRES]
after_IN
15_CD
December_NN
2005_CD
._.
amortised_VBN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
there_EX
is_VPRT
an_DT
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
154_CD
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
equivalent_JJ
requirement_NOMZ
,_,
but_CC
the_DT
effective_JJ
to_TO
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
results_NN
or_CC
net_JJ
date_NN
was_VBD [BEMA]
1_CD
January_NN
2002_CD
._.
assets_NN
of_PIN
AstraZeneca_NN
._.
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
131_CD
NET_NN
INCOME_NN
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
significant_JJ
difference_NN
between_PIN
the_DT
IFRS_NN
and_PHC
US_FPP1
GAAP_NN
treatment_NOMZ
of_PIN
the_DT
combination_NOMZ
of_PIN
Astra_NN
and_PHC
Zeneca_NN
in_PIN
the_DT
year_NN
of_PIN
acquisition_NOMZ
,_,
and_ANDC
in_PIN
the_DT
results_NN
of_PIN
preceding_VBG
periods_NN
,_,
condensed_JJ
statements_NOMZ
of_PIN
operations_NOMZ
and_PHC
cash_NN
flow_NN
under_IN
US_FPP1
GAAP_NN
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
the_DT
benefit_NN
of_PIN
US_FPP1
investors_NN
._.
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
adjustments_NOMZ
to_PIN
net_JJ
income_NN
and_PHC
shareholders_NN
equity_NOMZ
which_WDT [WHSUB]
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
IFRS_NN
._.
2004 2003 2005_CD
restated_VBN
restated_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
for_PIN
the_DT
period_NN
under_IN
IFRS_NN
4,706_CD
3,664_CD
3,022_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
US_FPP1
GAAP_NN
Purchase_NN
accounting_GER
adjustments_NOMZ
including_VBG [WZPRES]
goodwill_NN
and_CC
intangibles_VPRT
Deemed_JJ
acquisition_NOMZ
of_PIN
Astra_NN
Amortisation_NOMZ
and_CC
other_JJ
acquisition_NOMZ
adjustments_NOMZ
1,019_CD
1,014_CD
952_CD
Others_NN
Capitalisation_NOMZ
,_,
less_JJ
disposals_NN
and_PHC
amortisation_NOMZ
of_PIN
interest_NN
13_CD
1_CD
17_CD
Deferred_VBN
taxation_NOMZ
On_PIN
fair_JJ
values_NN
of_PIN
Astra_NN
283 283 266_CD
Others_NN
65_CD
55_CD
178_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
benefits_NN
expense_NN
74_CD
52_CD
23_CD
Financial_NN
instruments_NOMZ
35_CD
61_CD
1_CD
In-licensed_JJ
development_NOMZ
intangibles_VPRT
29_CD
46_CD
21_CD
Deferred_JJ
income_NN
recognition_NOMZ
14_CD
Unrealised_JJ
losses_NN
on_PIN
foreign_JJ
exchange_NN
and_PHC
others_NN
13_CD
Net_JJ
income_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
3,884_CD
2,951_CD
2,149_CD
Restated_VBN
in_PIN
respect_NN
of_PIN
SFAS_NN
123_CD
R_NN
US_FPP1
GAAP_NN
CONDENSED_NN
CONSOLIDATED_NN
STATEMENT_NOMZ
OF_PIN
OPERATIONS_NOMZ
2004 2003 2005_CD
restated_VBN
restated_VBN
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Sales_NN
23,950_CD
21,426_CD
18,849_CD
Cost_NN
of_PIN
sales_NN
5,356_CD
5,152_CD
4,471_CD
Distribution_NOMZ
costs_NN
211 177 162_CD
Research_NN
and_PHC
development_NOMZ
3,429_CD
3,900_CD
3,493_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
8,783_CD
8,003_CD
7,036_CD
Amortisation_NOMZ
of_PIN
intangibles_NN
1,009_CD
953_CD
881_CD
Other_JJ
income_NN
193 534 225_CD
Operating_GER
income_NN
5,355_CD
3,775_CD
3,031_CD
Net_JJ
interest_NN
income_NN
expense_NN
123_CD
1_CD
63_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
taxation_NOMZ
5,478_CD
3,774_CD
3,094_CD
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
1,594_CD
823_CD
945_CD
Net_JJ
income_NN
from_PIN
continuing_VBG
operations_NOMZ
3,884_CD
2,951_CD
2,149_CD
Net_JJ
income_NN
for_PIN
the_DT
year_NN
3,884_CD
2,951_CD
2,149_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
$_$
0.25_CD
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
1,617_CD
1,673_CD
1,709_CD
Dilutive_JJ
impact_NN
of_PIN
share_NN
options_NOMZ
outstanding_JJ
millions_NN
1_CD
23_CD
Diluted_NN
weighted_JJ
average_JJ
number_NN
of_PIN
$_$
0.25_CD
Ordinary_NN
Shares_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
millions_NN
1,618_CD
1,675_CD
1,712_CD
Net_JJ
income_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_PHC
diluted_JJ
$_$
2.40_CD
$_$
1.76_CD
$_$
1.26_CD
Restated_VBN
in_PIN
respect_NN
of_PIN
SFAS_NN
123_CD
R_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
132_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
ADDITIONAL_NN
INFORMATION_NOMZ
FOR_PIN
US_FPP1
INVESTORS_NN
CONTINUED_VBD
US_FPP1
GAAP_NN
STATEMENT_NOMZ
OF_PIN
COMPREHENSIVE_NN
INCOME_NN
2004 2003 2005_CD
restated_VBN
restated_VBN
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
for_PIN
the_DT
year_NN
3,884_CD
2,951_CD
2,149_CD
Exchange_NN
losses_NN
gains_NN
,_,
net_NN
of_PIN
tax_NN
3,279_CD
2,106_CD
3,635_CD
Other_JJ
movements_NOMZ
,_,
net_NN
of_PIN
tax_NN
218_CD
20_CD
81_CD
Total_JJ
comprehensive_JJ
income_NN
823_CD
5,077_CD
5,703_CD
Restated_VBN
in_PIN
respect_NN
of_PIN
SFAS_NN
123_CD
R_NN
Other_JJ
movements_NOMZ
in_PIN
2005_CD
include_VPRT
a_DT
reduction_NOMZ
in_PIN
the_DT
minimum_JJ
liability_NOMZ
under_IN
SFAS_NN
No._NN
._.
87_CD
Employers_NN
Accounting_GER
for_PIN
Pensions_NN
from_PIN
$_$
253m_CD
to_TO
$_$
36m_CD
._.
Tax_NN
effects_NN
on_PIN
exchange_NN
gains_NN
losses_NN
were_VBD
$_$
46_CD
m_NN
and_CC
on_PIN
other_JJ
movements_NOMZ
$_$
61m_CD
._.
The_DT
cumulative_JJ
exchange_NN
gains_NN
and_PHC
losses_NN
net_NN
of_PIN
tax_NN
on_PIN
the_DT
translation_NOMZ
of_PIN
foreign_JJ
currency_NN
financial_JJ
statements_NOMZ
under_IN
US_FPP1
GAAP_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
following_JJ
note_NN
:_:
2004 2003 2005_CD
restated_VBN
restated_VBN
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Balance_NN
at_PIN
1_CD
January_NN
4,342_CD
2,236_CD
1,399_CD
Movement_NOMZ
in_PIN
year_NN
3,279_CD
2,106_CD
3,635_CD
Balance_NN
at_PIN
31_CD
December_NN
1,063_CD
4,342_CD
2,236_CD
Restated_VBN
in_PIN
respect_NN
of_PIN
SFAS_NN
123_CD
R_NN
The_DT
cumulative_JJ
total_NN
of_PIN
other_JJ
movements_NOMZ
net_NN
of_PIN
tax_NN
at_PIN
31_CD
December_NN
2005_CD
was_VBD [BEMA]
a_DT
credit_NN
of_PIN
$_$
84m_CD
2004_CD
charge_NN
of_PIN
$_$
134m_CD
,_,
2003_CD
charge_NN
of_PIN
$_$
154m_CD
._.
STOCK-BASED_JJ
COMPENSATION_NOMZ
The_NN
Group_NN
has_VPRT [PEAS]
adopted_VBN
SFAS_NN
No._NN
._.
123_CD
R_NN
Share-Based_NN
Payments_NOMZ
in_PIN
the_DT
year_NN
under_IN
review_NN
in_PIN
respect_NN
of_PIN
share_NN
options_NOMZ
granted_VBN [SUAV]
and_PHC
has_VPRT [PEAS]
applied_VBN
its_PIT
provisions_NN
retrospectively_RB
._.
The_DT
effects_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
,_,
income_NN
before_IN
tax_NN
,_,
net_JJ
income_NN
and_CC
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
table_NN
below_PLACE
._.
There_EX
were_VBD
no_SYNE
impacts_NN
from_PIN
adoption_NOMZ
on_PIN
the_DT
cash_NN
flows_VPRT
of_PIN
the_DT
Group_NN
._.
2005 2004 2003_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
128 147 154_CD
Income_NN
before_IN
tax_NN
128 147 154_CD
Net_JJ
income_NN
100 107 111_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_PHC
diluted_JJ
$_$
0.06_CD
$_$
0.06_CD
$_$
0.06_CD
The_DT
total_JJ
compensation_NOMZ
cost_NN
for_PIN
nonvested_JJ
awards_NN
not_XX0
yet_RB
recognized_VBN [PRIV]
at_PIN
31_CD
December_NN
2005_CD
was_VBD
approximately_RB
$_$
137m_CD
and_CC
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
over_IN
a_DT
weighted_JJ
average_JJ
period_NN
of_PIN
21_CD
months_NN
._.
$_$
143m_CD
was_VBD [PASS]
received_VBN
during_PIN
2005_CD
from_PIN
the_DT
exercise_NN
of_PIN
share_NN
options_NOMZ
and_CC
similar_JJ
instruments_NOMZ
granted_VBN [SUAV]
under_IN
share-based_JJ
payment_NOMZ
arrangements_NOMZ
and_CC
$_$
3.9_CD
m_NN
tax_NN
benefit_NN
was_VBD [PASS]
realized_VBN [PRIV]
from_PIN
share_NN
options_NOMZ
exercised_VBN [WZPAST]
during_PIN
the_DT
year_NN
._.
PENSION_NN
AND_PHC
POST-RETIREMENT_NOMZ
BENEFITS_NN
For_PIN
the_DT
purposes_NN
of_PIN
US_FPP1
GAAP_NN
,_,
the_DT
pension_NN
information_NOMZ
as_IN
set_VBN
out_PIN
in_PIN
Note_NN
23_CD
in_PIN
respect_NN
of_PIN
the_DT
UK_NN
retirement_NOMZ
plans_NN
and_CC
of_PIN
the_DT
retirement_NOMZ
plans_NN
of_PIN
the_DT
non-UK_JJ
subsidiaries_NN
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
in_PIN
the_DT
following_VBG
tables_NN
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
No._NN
._.
132_CD
Employers_NN
Disclosures_NN
about_IN
Pensions_NN
and_CC
Other_JJ
Postretirement_NOMZ
Benefits_NN
,_,
an_DT
amendment_NOMZ
of_PIN
FASB_NN
Statements_NOMZ
No._NN
._.
These_DEMO
plans_NN
comprise_VPRT
substantially_RB
all_QUAN
of_PIN
the_DT
actuarial_JJ
liabilities_NOMZ
of_PIN
all_QUAN
AstraZeneca_NN
retirement_NOMZ
plans_NN
._.
The_DT
changes_NN
in_PIN
projected_VBN
benefit_NN
obligations_NOMZ
,_,
plan_NN
assets_NN
and_PHC
details_NN
of_PIN
the_DT
funded_JJ
status_NN
of_PIN
these_DEMO
retirement_NOMZ
plans_NN
,_,
together_RB
with_PIN
the_DT
changes_NN
in_PIN
the_DT
accumulated_VBN
other_JJ
post-retirement_JJ
benefit_NN
obligations_NOMZ
,_,
under_IN
SFAS_NN
No._NN
._.
132_CD
are_VPRT
as_IN
follows_VPRT
:_:
Pension_NN
benefits_NN
Other_JJ
post-retirement_NOMZ
benefits_NN
2005 2004 2003 2005_CD
2004_CD
2003_CD
Change_NN
in_PIN
projected_VBN
benefit_NN
obligation_NOMZ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Benefit_NN
obligation_NOMZ
at_PIN
beginning_GER
of_PIN
year_NN
8,707_CD
7,416_CD
5,943_CD
249 242 210_CD
Service_NN
cost_NN
256 229 171_CD
12_CD
11_CD
9_CD
Interest_NN
cost_NN
419 385 329_CD
14_CD
14_CD
14_CD
Participant_NN
contributions_NOMZ
31_CD
30_CD
26_CD
1_CD
11_CD
Actuarial_JJ
loss_NN
gain_NN
764 328 545_CD
1_CD
3_CD
24_CD
Settlement_NOMZ
and_PHC
curtailment_NOMZ
10_CD
5_CD
Benefits_NN
paid_VBN
305 281 245_CD
15_CD
18_CD
19_CD
Exchange_NN
825 590 642_CD
3_CD
23_CD
Benefit_NN
obligation_NOMZ
at_PIN
end_NN
of_PIN
year_NN
9,047_CD
8,707_CD
7,416_CD
257 249 242_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
133_CD
PENSION_NN
AND_PHC
POST-RETIREMENT_NOMZ
BENEFITS_NN
CONTINUED_VBD
Pension_NN
benefits_NN
Other_JJ
post-retirement_NOMZ
benefits_NN
2005 2004 2003 2005_CD
2004_CD
2003_CD
Change_NN
in_PIN
plan_NN
assets_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Fair_NN
value_NN
at_PIN
beginning_GER
of_PIN
year_NN
6,972_CD
5,905_CD
4,549_CD
217 195 133_CD
Actual_JJ
return_NN
on_PIN
plan_NN
assets_NN
1,134_CD
565_CD
590_CD
13_CD
22_CD
35_CD
Group_NN
contribution_NOMZ
165 280 489_CD
13_CD
17_CD
43_CD
Participant_NN
contributions_NOMZ
31_CD
30_CD
26_CD
1_CD
1_CD
Benefits_NN
paid_VBD
305 281 245_CD
15_CD
17_CD
17_CD
Exchange_NN
629 473 496_CD
1_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
7,368_CD
6,972_CD
5,905_CD
230 217 195_CD
Funded_VBN
status_NN
of_PIN
plans_NN
1,679_CD
1,735_CD
1,511_CD
27_CD
32_CD
47_CD
Unrecognised_JJ
net_JJ
loss_NN
1,420_CD
1,644_CD
1,503_CD
32_CD
29_CD
36_CD
Prior_RB
service_NN
cost_NN
not_XX0
recognized_VBN [PRIV]
25_CD
15_CD
25_CD
8_CD
11_CD
9_CD
Unrecognised_JJ
net_JJ
obligation_NOMZ
on_PIN
implementation_NOMZ
1_CD
1_CD
19_CD
25_CD
29_CD
234_CD
77_CD
16_CD
16_CD
11_CD
9_CD
Adjustments_NOMZ
to_TO
recognize_VB [PRIV]
minimum_JJ
liability_NOMZ
:_:
Intangible_JJ
assets_NN
36_CD
39_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
36 217 260_CD
Accrued_VBN
benefit_NN
liability_NOMZ
asset_NN
270 330 283_CD
16_CD
11_CD
9_CD
At_PIN
31_CD
December_NN
2005_CD
,_,
the_DT
projected_VBN
benefit_NN
obligation_NOMZ
,_,
accumulated_VBN
benefit_NN
obligation_NOMZ
and_CC
fair_JJ
value_NN
of_PIN
the_DT
plan_NN
assets_NN
in_PIN
respect_NN
of_PIN
the_DT
pension_NN
plans_NN
above_PLACE
with_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
in_PIN
excess_NN
of_PIN
plan_NN
assets_NN
were_VBD
$_$
6,984_CD
m_NN
,_,
$_$
5,990_CD
m_NN
and_CC
$_$
5,566_CD
m_NN
,_,
2004_CD
$_$
6,699_CD
m_NN
,_,
$_$
5,800_CD
m_NN
and_CC
$_$
5,220_CD
m_NN
respectively_RB
._.
The_DT
total_NN
of_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
for_PIN
the_DT
pension_NN
plans_NN
was_VBD
$_$
7,965_CD
m_NN [BEMA]
2004_CD
$_$
7,443_CD
m._FW
The_DT
measurement_NOMZ
date_NN
for_PIN
the_DT
plan_NN
assets_NN
and_PHC
benefit_NN
obligations_NOMZ
set_VBN [WZPAST]
out_PIN
above_PLACE
was_VBD [BEMA]
31_CD
December_NN
2005_CD
._.
Contributions_NOMZ
to_PIN
the_DT
plans_NN
in_PIN
2006_CD
are_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
be_VB
$_$
163m_CD
._.
Following_VBG [PRESP]
an_DT
employee_NN
vote_NN
in_PIN
December_NN
2005_CD
,_,
and_ANDC
subject_JJ
to_PIN
regulatory_JJ
approval_NN
,_,
the_DT
Japanese_JJ
defined_VBN
benefit_NN
pension_NN
scheme_NN
is_VPRT
to_TO
be_VB [PASS]
closed_VBN
and_CC
its_PIT
assets_NN
and_PHC
obligations_NOMZ
transferred_VBN [WZPAST]
to_PIN
a_DT
defined_VBN
contribution_NOMZ
scheme_NN
._.
The_DT
curtailment_NOMZ
and_PHC
settlement_NOMZ
cost_NN
,_,
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
2006_CD
,_,
will_PRMD
be_VB
approximately_RB
$_$
35m_CD
and_CC
the_DT
cash_NN
payment_NOMZ
in_PIN
the_DT
region_NN
of_PIN
$_$
100m_CD
._.
Assumed_VBN [PRIV]
discount_NN
rates_NN
and_PHC
rates_NN
of_PIN
increase_NN
in_PIN
remuneration_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
projected_VBN
benefit_NN
obligations_NOMZ
together_RB
with_PIN
long_JJ
term_NN
rates_NN
of_PIN
return_NN
on_PIN
plan_NN
assets_NN
vary_VPRT
according_VBG
to_PIN
the_DT
economic_JJ
conditions_NOMZ
of_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
retirement_NOMZ
plans_NN
are_VPRT [PASS]
situated_VBN
._.
The_DT
weighted_JJ
average_NN
rates_NN
used_VBN [WZPAST]
for_PIN
calculation_NOMZ
of_PIN
year_NN
end_NN
benefit_NN
obligations_NOMZ
and_PHC
forecast_NN
benefit_NN
cost_NN
in_PIN
the_DT
retirement_NOMZ
plans_NN
and_CC
other_JJ
benefit_NN
obligations_NOMZ
for_PIN
SFAS_NN
No._NN
._.
132_CD
purposes_NN
were_VBD
as_IN
follows_VPRT
:_:
Pension_NN
benefits_NN
Other_JJ
post-retirement_NOMZ
benefits_NN
2005 2004 2003 2005_CD
2004_CD
2003_CD
%_NN
%_NN
%_NN
%_NN
%_NN
%_NN
Discount_NN
rate_NN
4.8_CD
5.2_CD
5.5_CD
5.4_CD
5.7_CD
5.9_CD
Long_JJ
term_NN
rate_NN
of_PIN
increase_NN
in_PIN
remuneration_NOMZ
3.8_CD
3.9_CD
4.0_CD
n_VBD
a_DT
n_NN
a_DT
n_NN
a_DT
Expected_VBN [PRIV]
long_JJ
term_NN
return_NN
on_PIN
assets_NN
6.4_CD
6.8_CD
6.6_CD
6.5_CD
7.8_CD
7.8_CD
The_DT
Group_NN
has_VPRT [PEAS]
assumed_VBN [PRIV]
a_DT
long_JJ
term_NN
rate_NN
of_PIN
increase_NN
in_PIN
healthcare_NN
costs_NN
of_PIN
9.9_CD
%_NN
,_,
reducing_VBG [PRESP]
to_PIN
4.9_CD
%_NN
._.
Pension_NN
benefits_NN
Other_JJ
post-retirement_NOMZ
benefits_NN
2005 2004 2003 2005_CD
2004_CD
2003_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
periodic_JJ
cost_NN
Service_NN
cost_NN
present_JJ
value_NN
of_PIN
benefits_NN
accruing_VBG [WZPRES]
during_PIN
the_DT
year_NN
256 229 171_CD
12_CD
11_CD
9_CD
Interest_NN
cost_NN
on_PIN
projected_VBN
benefit_NN
obligations_NOMZ
419 385 329_CD
14_CD
14_CD
14_CD
Expected_VBN [PRIV]
return_NN
on_PIN
assets_NN
431 406 308_CD
17_CD
15_CD
14_CD
Net_JJ
amortisation_NOMZ
and_CC
deferral_JJ
111_CD
76_CD
45_CD
3_CD
32_CD
Net_JJ
periodic_JJ
cost_NN
for_PIN
the_DT
year_NN
355 284 237_CD
12_CD
13_CD
11_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
134_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
ADDITIONAL_NN
INFORMATION_NOMZ
FOR_PIN
US_FPP1
INVESTORS_NN
CONTINUED_VBD
PENSION_NN
AND_PHC
POST-RETIREMENT_NOMZ
BENEFITS_NN
CONTINUED_VBD
The_DT
weighted_JJ
average_JJ
allocation_NOMZ
of_PIN
pension_NN
and_CC
other_JJ
post-retirement_JJ
plan_NN
assets_NN
was_VBD
as_IN
follows_VPRT
:_:
2005 2004 2003_CD
%_NN
%_NN
%_NN
Equities_NOMZ
46.6_CD
48.2_CD
49.2_CD
Bonds_NN
37.5_CD
35.6_CD
48.8_CD
Other_JJ
15.9_CD
16.2_CD
2.0_CD
The_DT
benefits_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
in_PIN
the_DT
future_NN
are_VPRT
as_IN
follows_VPRT
:_:
$_$
m_CD [BEMA]
2006 295 2007 306_CD
2008 319 2009 332_CD
2010 344 2011 2015_CD
1,909_CD
TAXATION_NOMZ
2004 2003 2005_CD
restated_VBN
restated_VBN
Years_NN
ended_VBD
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
Current_JJ
tax_NN
expense_NN
Current_JJ
year_NN
1,747_CD
1,349_CD
902_CD
Adjustment_NOMZ
for_PIN
prior_JJ
years_NN
112_CD
171_CD
26_CD
Deferred_JJ
tax_NN
expense_NN
Origination_NOMZ
and_PHC
reversal_NN
of_PIN
temporary_JJ
differences_NN
265_CD
355_CD
17_CD
Total_JJ
taxation_NOMZ
expense_NN
in_PIN
the_DT
income_NN
statement_NOMZ
1,594_CD
823_CD
945_CD
Restated_VBN
in_PIN
respect_NN
of_PIN
SFAS_NN
123_CD
R_NN
The_DT
table_NN
below_PLACE
reconciles_NN
the_DT
UK_NN
statutory_JJ
tax_NN
charge_NN
with_PIN
the_DT
Groups_NN
actual_JJ
charge_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
._.
2004 2003 2005_CD
restated_VBN
restated_VBN
Years_NN
ended_VBD
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
5,478_CD
3,774_CD
3,094_CD
Taxation_NOMZ
charge_NN
at_PIN
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
for_PIN
2005_CD
30_CD
%_NN
for_PIN
2004_CD
,_,
30_CD
%_NN
for_PIN
2003_CD
1,644_CD
1,132_CD
928_CD
Differences_NN
in_PIN
effective_JJ
overseas_PLACE
tax_NN
rates_NN
147_CD
2_CD
41_CD
Unrecognised_JJ
deferred_JJ
tax_NN
asset_NN
25_CD
25_CD
Items_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
136_CD
30_CD
111_CD
Items_NN
not_XX0
chargeable_JJ
for_PIN
tax_NN
purposes_NN
95_CD
71_CD
88_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
31_CD
171_CD
35_CD
Exceptional_JJ
items_NN
124_CD
Tax_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
1,594_CD
823_CD
945_CD
Restated_VBN
in_PIN
respect_NN
of_PIN
SFAS_NN
123_CD
R_NN
In_PIN
2005_CD
,_,
claims_VPRT [PUBV]
amounting_VBG
to_TO
$_$
nil_JJ
2004_CD
$_$
nil_CD
,_,
2003_CD
$_$
95m_CD
for_PIN
tax_NN
relief_NN
were_VBD [PASS]
made_VBN
arising_VBG
as_CONJ
a_NULL
result_NULL
of_PIN
a_DT
restructuring_GER
of_PIN
the_DT
AMI_NN
joint_JJ
venture_NN
in_PIN
1998_CD
._.
Under_IN
US_FPP1
GAAP_NN
,_,
these_DEMO
reliefs_NN
are_VPRT [PASS]
adjusted_VBN
against_PIN
the_DT
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
restructuring_GER
and_CC
included_VBD
in_PIN
other_JJ
adjustments_NOMZ
._.
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
135_CD
SHAREHOLDERS_NN
EQUITY_NOMZ
2004 2003 2005_CD
restated_VBN
restated_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Total_JJ
shareholders_NN
equity_NOMZ
under_IN
IFRS_NN
13,597_CD
14,404_CD
13,086_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
US_FPP1
GAAP_NN
Purchase_NN
accounting_GER
adjustments_NOMZ
including_VBG [WZPRES]
goodwill_NN
and_CC
intangibles_VPRT
Deemed_JJ
acquisition_NOMZ
of_PIN
Astra_NN
Goodwill_NN
13,504_CD
15,130_CD
14,342_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_CC
intangible_JJ
assets_NN
5,229_CD
6,988_CD
7,661_CD
Others_NN
58_CD
99_CD
55_CD
Capitalisation_NOMZ
,_,
less_JJ
disposals_NN
and_PHC
amortisation_NOMZ
of_PIN
interest_NN
241 254 255_CD
Deferred_JJ
taxation_NOMZ
On_PIN
fair_JJ
value_NN
of_PIN
Astra_NN
1,629_CD
2,134_CD
2,313_CD
Others_NN
492 618 555_CD
In-licensed_JJ
development_NOMZ
intangibles_VPRT
112_CD
83_CD
38_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
benefits_NN
1,483_CD
1,418_CD
1,212_CD
Financial_NN
instruments_NOMZ
18_CD
22_CD
57_CD
Others_NN
3_CD
3_CD
3_CD
Shareholders_NN
equity_NOMZ
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
31,894_CD
35,477_CD
33,759_CD
Restated_VBN
in_PIN
respect_NN
of_PIN
SFAS_NN
123_CD
R_NN
ACQUIRED_VBN
INTANGIBLE_JJ
ASSETS_NN
AND_PHC
GOODWILL_NN
Details_NN
of_PIN
the_DT
carrying_VBG
amounts_NN
of_PIN
intangible_JJ
assets_NN
and_CC
past_JJ
and_CC
projected_VBD
amortisation_NOMZ
expenses_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
2005 2004 2003_CD
Gross_NN
Gross_NN
Gross_NN
carrying_VBG [WZPRES]
Accumulated_NN
carrying_VBG [WZPRES]
Accumulated_NN
carrying_VBG [WZPRES]
Accumulated_NN
amount_NN
amortisation_NOMZ
amount_NN
amortisation_NOMZ
amount_NN
amortisation_NOMZ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Product_NN
rights_NN
12,961_CD
7,011_CD
14,590_CD
6,744_CD
13,733_CD
5,274_CD
Marketing_GER
and_PHC
distribution_NOMZ
rights_NN
1,494_CD
1,043_CD
1,729_CD
1,043_CD
1,659_CD
831_CD
Software_NN
652 396 589 367_CD
462_CD
305_CD
Others_NN
437 310 460 360_CD
421_CD
329_CD
Total_JJ
15,544_CD
8,760_CD
17,368_CD
8,514_CD
16,275_CD
6,739_CD
Aggregate_NN
amortisation_NOMZ
expense_NN
$_$
m_CD [BEMA]
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2005_CD
1,287_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2004_CD
1,316_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2003_CD
1,245_CD
Estimated_VBN [PRIV]
amortisation_NOMZ
expense_NN
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2006_CD
1,275_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2007_CD
1,187_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2008_CD
1,187_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2009_CD
1,187_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2010_CD
1,187_CD
The_DT
weighted_JJ
average_JJ
amortisation_NOMZ
period_NN
in_PIN
respect_NN
of_PIN
each_QUAN
class_NN
of_PIN
intangible_JJ
asset_NN
is_VPRT
as_IN
follows_VPRT
:_:
Product_NN
rights_NN
13_CD
years_NN
Marketing_GER
and_PHC
distribution_NOMZ
rights_NN
16_CD
years_NN
Software_NN
4_CD
years_NN
Other_JJ
8_CD
years_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
136_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
ACQUIRED_NN
INTANGIBLE_NN
ASSETS_NN
AND_PHC
GOODWILL_NN
CONTINUED_VBD
Goodwill_NN
The_NN
changes_NN
in_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
goodwill_NN
for_PIN
the_DT
three_CD
years_NN
ended_VBN
31_CD
December_NN
2005_CD
were_VBD
as_IN
follows_VPRT
:_:
$_$
m_CD
Balance_NN
as_IN
at_PIN
1_CD
January_NN
2003_CD
13,647_CD
Acquired_VBN
1_CD
Exchange_NN
movements_NOMZ
1,658_CD
Balance_NN
as_IN
at_PIN
31_CD
December_NN
2003_CD
15,306_CD
Exchange_NN
movements_NOMZ
837_CD
Balance_NN
as_IN
at_PIN
31_CD
December_NN
2004_CD
16,143_CD
Exchange_NN
movements_NOMZ
1,737_CD
Balance_NN
as_IN
at_PIN
31_CD
December_NN
2005_CD
14,406_CD
US_FPP1
GAAP_NN
CONDENSED_NN
CONSOLIDATED_NN
STATEMENT_NOMZ
OF_PIN
CASH_NN
FLOWS_NN
2005 2004 2003_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cash_NN
flows_VPRT
from_PIN
operating_VBG
activities_NOMZ
6,919_CD
4,842_CD
3,416_CD
Cash_NN
flows_VPRT
from_PIN
investing_VBG
activities_NOMZ
Movement_NOMZ
in_PIN
short_JJ
term_NN
investments_NOMZ
and_CC
fixed_VBN
deposits_NN
1,922_CD
862_CD
771_CD
New_NN
non-current_JJ
investments_NOMZ
12 117 120_CD
Disposal_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
87_CD
35_CD
38_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
355_CD
80_CD
Capital_NN
expenditure_NN
942_CD
1,183_CD
1,515_CD
Net_JJ
cash_NN
outflows_NN
from_PIN
investing_VBG
activities_NOMZ
2,789_CD
1,772_CD
746_CD
Net_JJ
cash_NN
flow_NN
before_IN
financing_VBG
4,130_CD
3,070_CD
2,670_CD
Cash_NN
flows_VPRT
from_PIN
financing_VBG
activities_NOMZ
Equity_NOMZ
dividends_NN
paid_VBD
1,717_CD
1,378_CD
1,222_CD
Proceeds_NN
from_PIN
issue_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
143_CD
102_CD
47_CD
Re-purchase_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
3,001_CD
2,212_CD
1,154_CD
Net_JJ
increase_NN
in_PIN
short_JJ
term_NN
borrowings_GER
3_CD
2_CD
New_JJ
loans_NN
loans_NN
repaid_VBN
725_CD
345_CD
Net_JJ
cash_NN
outflows_NN
from_PIN
financing_VBG
activities_NOMZ
4,572_CD
2,761_CD
2,674_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
442_CD
309_CD
4_CD
Cash_NN
:_:
At_PIN
1_CD
January_NN
915 581 524_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
442_CD
309_CD
4_CD
Exchange_NN
movements_NOMZ
12_CD
25_CD
61_CD
At_PIN
31_CD
December_NN
461 915 581_CD
Interest_NN
paid_VBN [WZPAST]
was_VBD
$_$
32m_CD
in_PIN
2005_CD
2004_CD
$_$
69m_CD
,_,
2003_CD
$_$
39m_CD
._.
